Clinical Trial · NCT06769893

A Prospective, Open-label, Single-center Study of CD70-Specific PET/CT Imaging for Non-invasive Diagnosis of Renal Cell Carcinoma

Overview

This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included. Qualified subjects will undergo 68Ga-NOTA-RCCB6 PET/CT examination. The aim is to establish the optimal imaging protocol; evaluate the distribution characteristics and correlations of physiological and pathological positive uptake, and using pathological results as the gold standard, assess the diagnostic efficacy of 68Ga-NOTA-RCCB6 PET/CT in renal cell carcinoma.

Sponsor

Xijing Hospital

Phase

N/A

Contacts

Ying Guo

guoying01192022@163.com

0086+15991459177

ClinicalTrials.gov

NCT06769893

Drug / Compound

68Ga-NOTA-RCCB6

Isotope(s):
Target(s):
  • CD70
Chelator: NOTA